Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Bays HE, et al. Among authors: kashyap ml. Am J Cardiol. 2003 Mar 15;91(6):667-72. doi: 10.1016/s0002-9149(03)00007-9. Am J Cardiol. 2003. PMID: 12633795 Clinical Trial.
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Guyton JR, et al. Among authors: kashyap ml. J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31. J Am Coll Cardiol. 2013. PMID: 23916935 Free PMC article. Clinical Trial.
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Albers JJ, et al. Among authors: kashyap ml. J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973688 Free PMC article. Clinical Trial.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Lyubarova R, Albers JJ, Marcovina SM, Yao Y, McBride R, Topliceanu A, Anderson T, Fleg JL, Desvigne-Nickens P, Kashyap ML, McGovern ME, Boden WE. Lyubarova R, et al. Among authors: kashyap ml. J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):534-541. doi: 10.1177/1074248419852955. Epub 2019 May 26. J Cardiovasc Pharmacol Ther. 2019. PMID: 31131629 Clinical Trial.
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Probstfield JL, Boden WE, Anderson T, Branch K, Kashyap M, Fleg JL, Desvigne-Nickens P, McBride R, McGovern M; AIM-HIGH Investigators. Probstfield JL, et al. J Clin Lipidol. 2018 Nov-Dec;12(6):1413-1419. doi: 10.1016/j.jacl.2018.07.007. Epub 2018 Jul 25. J Clin Lipidol. 2018. PMID: 30131256
Mechanism of action of niacin.
Kamanna VS, Kashyap ML. Kamanna VS, et al. Among authors: kashyap ml. Am J Cardiol. 2008 Apr 17;101(8A):20B-26B. doi: 10.1016/j.amjcard.2008.02.029. Am J Cardiol. 2008. PMID: 18375237 Review.
163 results